Skip to main content
SpringerLink
Log in

Seborrheic Dermatitis

  • Chapter
  • First Online:
Dermatology in Public Health Environments

Abstract

Seborrheic dermatitis is a very prevalent inflammatory skin disorder. The affected skin presents as erythematous, edematous, and covered with scales (or even crusts) which are yellowish, erythematous, or brown. There are many associated factors whose recognition is important. A variety of available treatment modalities is discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74(1):125–30.

    PubMed  Google Scholar 

  2. Warner RR, et al. Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol. 2001;45(6):897–903.

    Article  PubMed  CAS  Google Scholar 

  3. Berkt T, Scheinfeld N. Seborrheic dermatitis. P T. 2010;35(6):348–52.

    Google Scholar 

  4. Szepietowski JC, et al. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses. 2009;52(4):357–63.

    Article  PubMed  Google Scholar 

  5. Kligman AM, Mcginley KJ, Leyden JJ. The nature of dandruff. J Soc Cosmet Chem. 1976;27:111–39.

    Google Scholar 

  6. Lynch PJ. Dermatologic problems of the head and neck in the aged. Otolaryngol Clin N Am. 1982;15(2):271–85.

    CAS  Google Scholar 

  7. Johnson ML, Johnson KG, ENGEL A. Prevalence, morbidity, and cost of dermatologic diseases. J Am Acad Dermatol. 1984;11(5):930–6.

    Article  PubMed  CAS  Google Scholar 

  8. Johnson MT, Roberts J. Skin conditions and related need for medical care among persons 1-74 years. United States, 1971-1974. Vital Health Stat. 1978;11:1–72.

    Google Scholar 

  9. Dawson TL. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J Investig Dermatol Symp Proc. 2007;12(2):15–9.

    Article  PubMed  CAS  Google Scholar 

  10. Dogliotti M. Skin disorders in the Bantu: a survey of 2.000 cases from Baragwanath Hospital. S Afr Med J. 1970;44(23):670–2.

    PubMed  CAS  Google Scholar 

  11. Mahe A, et al. Predictive value of seborrheic dermatitis and other common dermatoses for HIV infection in Bamako, Mali. J Am Acad Dermatol. 1996;34(6):1084–6.

    Article  PubMed  CAS  Google Scholar 

  12. Olumide YM, Odunowo BD, Odiase AO. Depigmentation in black African patients. Int J Dermatol. 1990;29(3):166–74.

    Article  PubMed  CAS  Google Scholar 

  13. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med. 2004;5(1):50–4.

    Article  PubMed  CAS  Google Scholar 

  14. Farthing CF, Staughton RCD, Rowland A, Payne CME. Skin disease in homosexual patients with acquired immune deficiency syndrome (AIDS) and lesser forms of human T cell leukaemia virus (HTLV III) disease. Clin Exp Dermatol. 1985;10(1):3–12.

    Article  PubMed  CAS  Google Scholar 

  15. Smith KJ, et al. Cutaneous findings in HIV-1 positive patients: a 42-month prospective study. J Am Acad Dermatol. 1994;31(5):746–54.

    Article  PubMed  CAS  Google Scholar 

  16. Burton JL, Pye RJ. Seborrhoea is not a feature of seborrhoeic dermatitis. Br Med J. 1983;286(6372):1169–70.

    Article  CAS  Google Scholar 

  17. Pilgram GS, et al. The influence of two azones and sebaceous lipids on the lateral organization of lipids isolated from human stratum corneum. Biochim Biophys Acta. 2001;1511(2):244–54.

    Article  PubMed  CAS  Google Scholar 

  18. Theile JJ, Weber SU, Packer L. Sebaceous gland activity is a major physiologic route of vitamin E delivery to the skin. J Invest Dermatol. 1999;113(6):1006–10.

    Article  Google Scholar 

  19. Thiboutot D, et al. Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol. 2003;120(6):905–14.

    Article  PubMed  CAS  Google Scholar 

  20. Zouboulis CC. Sebaceous gland in human skin—the fantastic future of a skin appendage. J Invest Dermatol. 2003;120(6):14–5.

    Article  Google Scholar 

  21. Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm Venereol Suppl (Stockh). 1991;167:1–36.

    CAS  Google Scholar 

  22. Shi VY, Leo M, Hassoun L, Chahal DS, Maibach HI, Sivamani RK. Role of sebaceous glands in inflammatory dermatoses. J Am Acad Dermatol. 2015;73(5):856–63.

    Article  PubMed  CAS  Google Scholar 

  23. Kim SY, Kim SH, Kim SN, Kim AR, Kim YR, Kim MJ, Park WS, Lee JH, Jung WH, Lee YW, Choe YB, Ahn KJ. Isolation and identification of Malassezia species from Chinese and Korean patients with seborrheic dermatitis and in vitro studies on their bioactivity on sebaceous lipids and IL-8 production. Mycoses. 2016;59(5):274–80.

    Article  PubMed  CAS  Google Scholar 

  24. Geissler SE, Michelsen S, Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges. 2003;1(12):952–8.

    Article  PubMed  Google Scholar 

  25. Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology. 2004;208(2):89–93.

    Article  PubMed  Google Scholar 

  26. Harding CR, et al. Dandruff: a condition characterized by decreased levels of intercellular lipids in scalp stratum corneum and impaired barrier function. Arch Dermatol Res. 2002;294(5):221–30.

    Article  PubMed  CAS  Google Scholar 

  27. Bettley FR, Marten RH. Unilateral seborrhoeic dermatitis following a nerve lesion. Arch Dermatol. 1956;73(2):110–5.

    Article  CAS  Google Scholar 

  28. Wilson CL, Walshe M. Incidence of seborrhoeic dermatitis in spinal injury patients. Br J Dermatol. 1988;119(33):48–8.

    Google Scholar 

  29. Tajima M, et al. Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J Invest Dermatol. 2008;128(2):345–51.

    Article  PubMed  CAS  Google Scholar 

  30. Batra R, et al. Malassezia Baillon, emerging clinical yeasts. FEMS Yeast Res. 2005;5(11):1101–13.

    Article  PubMed  CAS  Google Scholar 

  31. Ro BI, Dawson TL. The role of sebaceous gland activity and scalp microfloral metabolism in the etiology of seborrheic dermatitis and dandruff. J Investig Dermatol Symp Proc. 2005;10(3):194–7.

    Article  PubMed  CAS  Google Scholar 

  32. Rosenberg EW. Effect of topical applications of heavy suspensions of killed Malassezia ovalis on rabbit skin. Mycopathologia. 1980;72(3):147–52.

    Article  PubMed  CAS  Google Scholar 

  33. Faergemann J, et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol. 2001;144(3):549–56.

    Article  PubMed  CAS  Google Scholar 

  34. Deangelis YM, et al. Isolation and expression of a Malassezia globosa lipase gene, LIP1. J Invest Dermatol. 2007;127(9):2138–46.

    Article  PubMed  CAS  Google Scholar 

  35. Dietrich FS, et al. The Ashbya gossypii genome as a tool for mapping the ancient Saccharomyces cerevisiae genome. Science. 2004;304(5668):304–7.

    Article  PubMed  CAS  Google Scholar 

  36. Hermida L, et al. The Ashbya genome database (AGD) – a tool for the yeast community and genome biologists. Nucleic Acids Res. 2005;33(1):348–52.

    Google Scholar 

  37. Chen TA, Hill PB. The biology of Malassezia organisms and their ability to induce immune responses and skin disease. Vet Dermatol. 2005;16(1):4–26.

    Article  PubMed  Google Scholar 

  38. Thomas DS, et al. In vitro modulation of human keratinocyte pro- and anti- inflammatory cytokine production by the capsule of Malassezia species. FEMS Immunol Med Microbiol. 2008;54(2):203–14.

    Article  PubMed  CAS  Google Scholar 

  39. Xu J, et al. Dandruff-associated Malassezia genomes reveal convergent and divergent virulence traits shared with plant and human fungal pathogens. Proc Natl Acad Sci U S A. 2007;104(47):18730–5.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Rendic E, Diaz C, Fich F. Characterization of species of the gender Malassezia in patients with seborrheic dermatitis and subjects without skin lesions. Rev Med Chil. 2003;131(11):1295–300.

    Article  PubMed  Google Scholar 

  41. Baroni A, et al. New strategies in dandruff treatment: growth control of Malassezia ovalis. Dermatology. 2000;201(4):332–6.

    Article  PubMed  CAS  Google Scholar 

  42. Cohen S. Should we treat infantile seborrhoeic dermatitis with topical antifungals or topical steroids. Arch Dis Child. 2004;89(3):288–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Pierard GE, et al. Prolonged effects of antidandruff shampoos – time to recurrence of Malassezia ovalis colonization of skin. Int J Cosmet Sci. 1997;19(2):111–7.

    Article  PubMed  CAS  Google Scholar 

  44. Erchiga VC, Florencio VD. Malassezia species in skin diseases. Curr Opin Infect Dis. 2002;15(2):133–42.

    Article  Google Scholar 

  45. Pierard GE, Xhauflaires-Uhoda E, Pierard-Franchimont C. The key role of corneocytes in pityrosporoses. Dermatology. 2006;212(1):23–6.

    Article  PubMed  Google Scholar 

  46. Pierard-Franchimont C, et al. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Ski Physiol. 2001;15(6):434–41.

    Article  CAS  Google Scholar 

  47. Deangelis YM, et al. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol Symp Proc. 2005;10(3):295–7.

    Article  PubMed  Google Scholar 

  48. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol. 1998;139(2):254–63.

    Article  PubMed  CAS  Google Scholar 

  49. Wikler JR, Nieboer C, Willmenze R. Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis. J Am Acad Dermatol. 1992;27(1):37–9.

    Article  PubMed  CAS  Google Scholar 

  50. Prohic A, Kasumagic-Halilovic E. Identification of Malassezia species from immunocompetent and immunocompromised patients with seborrheic dermatitis. Eur Rev Med Pharmacol Sci. 1999;14(12):1019–23.

    Google Scholar 

  51. Kahlke B, Brasch J, Christophers E. Dermatophytes contain a novel lipid like leukocyte activator. J Invest Dermatol. 1996;107(1):108–12.

    Article  PubMed  CAS  Google Scholar 

  52. Mayser P, et al. Differentiation of Malassezia species: selectivity of Cremophor EL, castor oil and ricinoleic acid for M. furfur. Br J Dermatol. 1997;137(2):208–13.

    Article  PubMed  CAS  Google Scholar 

  53. Sampaio AL, Porto LC, Silva MR, Nunes AP, Oliveira JC, Silva GMF, Mameri A, Cassia FF, Carneiro SC. Human leucocyte antigen frequency in a miscegenated population presenting with seborrhoeic dermatitis. J Eur Acad Dermatol Venereol. 2014;28(11):1576–7.

    Article  PubMed  CAS  Google Scholar 

  54. Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatol Clin. 2003;21:401–12.

    Article  PubMed  Google Scholar 

  55. Breunig JA, et al. Scalp seborrheic dermatitis: prevalence and associated factors in male adolescents. Int J Dermatol. 2012;51(1):46–9.

    Article  Google Scholar 

  56. Breunig JA. Dermatite seborreica em adolescentes masculinos de 18 anos: prevalência e fatores associados em um estudo de base populacional. PhD thesis. PUCRS – Biblioteca Digital de Teses e Dissertações. Avaiable from: http://tede2.pucrs.br/tede2/handle/tede/1618; 2016.

  57. Dowlati B, et al. Insulin quantification in patients with seborrheic dermatitis. Arch Dermatol. 1998;134(8):1043–5.

    Article  PubMed  CAS  Google Scholar 

  58. Garcia HL. Dermatological complications of obesity. Am J Clin Dermatol. 2002;3(7):497–506.

    Article  Google Scholar 

  59. Ruiz Perez L, et al. Lipid profile and hormonal study in the school children of the province of Alicante. Endocrinol Nutr. 2009;56(4):158–63.

    Article  PubMed  Google Scholar 

  60. Lello S, et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol. 2008;24(12):718–23.

    Article  PubMed  CAS  Google Scholar 

  61. Raubrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63(5):463–92.

    Article  Google Scholar 

  62. Walker J, Adams B. Cutaneous manifestations of anabolic-androgenic steroid use in athletes. Int J Dermatol. 2009;48(10):1044–8.

    Article  PubMed  Google Scholar 

  63. Bourne S, Jabobs A. Observations on acne, seborrhoea, and obesity. Br Med J. 1956;1(4978):1268–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Linder D, Dreiher J, Zampetti A, Sampogna F, Cohen AD. Seborrheic dermatitis and hypertension in adults: a cross-sectional study. J Eur Acad Dermatol Venereol. 2014;28(11):1450–5.

    Article  PubMed  CAS  Google Scholar 

  65. Misery L, et al. Stress and seborrheic dermatitis. Ann Dermatol Venereol. 2007;134(11):833–7.

    Article  PubMed  CAS  Google Scholar 

  66. Berg M. Epidemiological studies of the influence of sunlight on the skin. Photo-Dermatology. 1989;6(2):80–4.

    PubMed  CAS  Google Scholar 

  67. Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol. 1983;63(4):335–9.

    PubMed  CAS  Google Scholar 

  68. Moehrle M, et al. High prevalence of seborrhoeic dermatitis on the face and scalp in mountain guides. Dermatology. 2000;201(2):146–7.

    Article  PubMed  CAS  Google Scholar 

  69. Yeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol. 2004;5(1):3–8.

    Article  PubMed  Google Scholar 

  70. Scheinfeld NS. Seborrheic dermatitis. Skinmed. 2005;4(1):49–50.

    Article  PubMed  Google Scholar 

  71. Pierard GE. Seborrheic dermatitis today, gone tomorrow? The link between the biocene and treatment. Dermatology. 2003;206(3):187–8.

    Article  PubMed  CAS  Google Scholar 

  72. Arsenijevic VSA, Milobratovic D, Barac AM, Vekic B, Marinkovic J, Kostic VS. A laboratory-based study on patients with Parkinson’s disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production. BMC Dermatol. 2014;14:5.

    Article  CAS  Google Scholar 

  73. Appenzeller O, Harville D. Effect of L-dopa on seborrhea of Parkinsonism. Lancet. 1970;2(7667):311–2.

    PubMed  CAS  Google Scholar 

  74. Marco-Llorente J, Rojo-Martinez E. Other non-motor disorders in Parkinson’s disease. Rev Neurol. 2010;50(2):75–83.

    Google Scholar 

  75. Mallal SA. The Western Australian HIV Cohort Study, Perth, Australia. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(1):23–7.

    Article  Google Scholar 

  76. Bonamigo RR, et al. Human T lymphotropic virus 1 and hepatitis virus as risk factors for inflammatory dermatoses in HIV-positive patients. Int J Dermatol. 2004;43(8):568–70.

    Article  PubMed  Google Scholar 

  77. Bittencourt AL, Oliveira MF. Cutaneous manifestations associated with HTLV-1 infection. Int J Dermatol. 2010;49(10):1099–110.

    Article  PubMed  Google Scholar 

  78. Ercis M, Balci S, Atakan N. Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetics unit. Clin Genet. 1996;50(5):317–20.

    PubMed  CAS  Google Scholar 

  79. Rocha N, et al. Cutaneous manifestations of familial amyloidotic polyneuropathy. J Eur Acad Dermatol Venereol. 2005;19(5):605–7.

    Article  PubMed  CAS  Google Scholar 

  80. Seite S, et al. A lipohydroxyacid-containing shampoo improves scalp condition and quality of life in patients with seborrheic dermatitis and light-to-moderate scalp psoriasis. J Cosmet Dermatol. 2009;8(2):108–13.

    Article  PubMed  CAS  Google Scholar 

  81. Foley P, et al. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol. 2003;139(3):318–22.

    Article  PubMed  Google Scholar 

  82. Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol. 1984;111(2):235–42.

    Article  PubMed  CAS  Google Scholar 

  83. Erlichman M, et al. Infantile flexural seborrhoeic dermatitis. Neither biotin nor essential fatty acid deficiency. Arch Dis Child. 1981;56(7):560–2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Xu C, Chen D, Liu J, Liu Y, Sun Q. Roles of dermoscopy in the diagnosis and differential diagnosis of scalp psoriasis and seborrheic dermatitis. Zhonghua Yi Xue Za Zhi. 2014;94(44):3467–70.

    PubMed  Google Scholar 

  85. Sampaio AL, Mameri AC, Vargas TJ, Silva MR, Nunes AP, Carneiro SC. Seborrheic dermatitis. An Bras Dermatol. 2011;86(6):1061–74.

    Article  PubMed  Google Scholar 

  86. Agozzino M, Berardesca E, Donadio C, Franceschini C, Felice CM, Cavallotti C, Sperduti I, Ardigò M. Reflectance confocal microscopy features of seborrheic dermatitis for plaque psoriasis differentiation. Dermatology. 2014;229(3):215–21.

    Article  PubMed  Google Scholar 

  87. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med. 2009;360(4):387–96.

    Article  PubMed  CAS  Google Scholar 

  88. Faergemann J, Fredriksson T. The antimycotic activity in vitro of five diols. Sabouraudia. 1980;18(4):287–93.

    Article  PubMed  CAS  Google Scholar 

  89. Bhatia N. Treating seborrheic dermatitis: review of mechanisms and therapeutic options. J Drugs Dermatol. 2013;12(7):796–8.

    PubMed  Google Scholar 

  90. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015;(5):CD008138.

    Google Scholar 

  91. Langtry JA, et al. Topical lithium succinate ointment (Efalith) in the treatment of AIDS-related seborrhoeic dermatitis. Clin Exp Dermatol. 1997;22(5):216–9.

    Article  PubMed  CAS  Google Scholar 

  92. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995;132(3):441–5.

    Article  PubMed  CAS  Google Scholar 

  93. Danby FW, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% xampu versus selenium sulfide 2.5% xampu in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993;29(6):1008–12.

    Article  PubMed  CAS  Google Scholar 

  94. Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. Ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol. 2007;21(3):345–50.

    Article  PubMed  CAS  Google Scholar 

  95. Marks R, Pearse AD, Walker AP. The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol. 1985;112(4):415–22.

    Article  PubMed  CAS  Google Scholar 

  96. Opdyke DL, Burnett CM, Brauer EW. Anti-seborrhoeic qualities of zinc pyrithione in a cream vehicle: II. Safety evaluation. Food Cosmet Toxicol. 1967;5(3):321–6.

    Article  PubMed  CAS  Google Scholar 

  97. Kastarinen H, Okokon E O, Verbeek JH. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp. Summary of a Cochrane Review. JAMA Dermatol Clin Evid Synop. 2015;151(2):221–2.

    Article  Google Scholar 

  98. Kim HO, Yang YS, Ko HC, Kim GM, Cho SH, Seo YJ, Son SW, Lee JR, Lee JS, Chang SE, Che JW, Park CW. Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment. Ann Dermatol. 2015;27(5):523–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Kim TW, et al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol. 2013;93:557–61.

    Article  PubMed  CAS  Google Scholar 

  100. Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of oral itraconazole in the treatment and relapse prevention of moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Am J Clin Dermatol. 2015;16(5):431–7.

    Article  PubMed  Google Scholar 

  101. Alizadeh N, Monadi Nori H, Golchi J, Eshkevari SS, Kazemnejad E, Darjani A. Comparison the efficacy of fluconazole and terbinafine in patients with moderate to severe seborrheic dermatitis. Dermatol Res Pract. 2014;20(14):402–705.

    Google Scholar 

  102. Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2014;28(1):16–26.

    Article  PubMed  CAS  Google Scholar 

  103. Abraham S, Piguet V. An unusual presentation of Malassezia dermatosis. Dermatology. 2016;212:4–6.

    Article  Google Scholar 

  104. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91(3):185–90.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Santa Cruz, UNISC, Santa Cruz do Sul, Brazil

    Juliano de Avelar Breunig

  2. Hospital Anchieta, Brasília, Brazil

    Marco Otavio Rocha Couto

Authors
  1. Juliano de Avelar Breunig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Otavio Rocha Couto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juliano de Avelar Breunig .

Editor information

Editors and Affiliations

  1. Dermatology Service of Clinical, Hospital of Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

    Renan Rangel Bonamigo

  2. Health Secretary of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil

    Sergio Ivan Torres Dornelles

Glossary

Calcineurin inhibitor

Calcineurin (CaN) is a calcium- and calmodulin-dependent serine/threonine protein phosphatase. Calcineurin inhibitors suppress the immune system by preventing interleukin-2 (IL-2) production in T cells.

Chemotaxis

A mechanism by which bacteria efficiently and rapidly respond to changes in the chemical composition of their environment, approaching chemically favorable environments and avoiding unfavorable ones.

Human leukocyte antigen (HLA)

The major histocompatibility complex (MHC) in humans, controlled by genes located on chromosome 6. It encodes cell surface molecules specialized to present antigenic peptides to the T-cell receptor (TCR) on T cells.

Psoralen

The parent compound in a family of natural products known as furocoumarins. Psoralen is a light-sensitive drug that absorbs ultraviolet (long wave, UVA) light and acts like ultraviolet radiation.

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing Switzerland

About this chapter

Cite this chapter

de Avelar Breunig, J., Couto, M.O.R. (2018). Seborrheic Dermatitis. In: Bonamigo, R., Dornelles, S. (eds) Dermatology in Public Health Environments. Springer, Cham. https://doi.org/10.1007/978-3-319-33919-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33919-1_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33917-7

  • Online ISBN: 978-3-319-33919-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation